lymphomas

(S)-Enitociclib (VIP152) is a selective CDK9 inhibitor that induces complete regression of MYC+ lymphomas by inhibiting RNA polymerase II-mediated transcription of anti-apoptotic and pro-survival proteins.

PG-11047 2HCl is an apoptosis-stimulating agent used in the treatment of genitourinary disorders, immune system disorders, genetic disorders and malformations, ocular disorders, and disorders of the blood and lymphatic systems, and in the study of lymphomas and prostate cancer.

Glofitamab (RO7082859) is a novel bivalent antibody directed against CD20-binding T cells.Glofitamab promotes T cell proliferation and activation and tumor cell killing by binding to CD20 on malignant cells.Glofitamab can be used for the palliation of relapsed or refractory B-cell lymphomas.

Tenatumomab (ST2146) is a murine anti-tenascin-C monoclonal antibody used in the study of immune system diseases and lymphomas.

Lenalidomide (sodium), a Thalidomide derivative, serves as a molecular glue and an orally active immunomodulator. It acts as a cereblon (CRBN) ligand and triggers selective ubiquitination and subsequent degradation of the lymphoid transcription factors IKZF1 and IKZF3 via the CRBN-CRL4 ubiquitin ligase. Echoing its specificity, Lenalidomide (sodium) inhibits the proliferation of mature B-cell lymphomas, notably multiple myeloma, and promotes IL-2 secretion from T cells [1] [2].

Lucatumumab (HCD122), a fully human anti-CD40 antagonist monoclonal antibody, effectively inhibits CD40/CD40L-mediated signaling and promotes antibody-dependent cell-mediated cytotoxicity (ADCC) for tumor cell clearance. It is applicable in refractory lymphomas, CLL, and multiple myeloma research [1] [2].

Polatuzumab vedotin, an antibody-drug conjugate, selectively targets CD79b with a humanized anti-CD79b IgG1 monoclonal antibody bound to monomethyl auristatin E (MMAE), a robust microtubule inhibitor. This compound shows promise for research into Large B-cell lymphomas (LBCL) [1].

4-hydroperoxy Cyclophosphamide (4-OOH-CY) is the active metabolite form of the prodrug Cyclophosphamide. 4-OOH-CY crosslinks DNA and induces T cell apoptosis independent of death receptor activation, but activates mitochondrial death pathways through production of reactive oxygen species (ROS).[1] Formulations containing the prodrug Cyclophosphamide are used to treat lymphomas and autoimmune disorders.[2],[3]

NSC10010 hydrochloride is an effective growth inhibitor for gammaherpesvirus-associated B-lymphomas. It acts through activation of both the NF-κB and c-Myc-mediated signaling pathways.

MAT2A-IN-9, a 2-oxoquinazoline derivative, is a potent MAT2A (methionine adenylyltransferase 2A) inhibitor.MAT2A-IN-9 has antitumor activity for the treatment of lymphomas and solid tumors.

Daunorubicin (Daunomycin) citrate, a potent anti-tumor anthracycline antibiotic, acts as a topoisomerase II inhibitor. It effectively inhibits DNA and RNA synthesis, diminishes cancer cell viability, and promotes apoptosis and necrosis. This cytotoxic compound is utilized in researching a range of cancers, such as leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, and Wilms' tumor, as well as infections [1] [2] [4] [5].

Prednimustine (Leo 1031;NSC 134087) is the ester formed from Prednisolone and Chlorambucil . Prednimustine can be used for leukemias and lymphomas research [1] .

DMBA (7,12-Dimethylbenz[a]anthracene) induces leukemia, hepatocellular carcinoma, and mammary carcinoma in rats, and programmed cell death (apoptosis) in B-cell lymphomas in A20.1 mice.

Cyclophosphamide-d4 is a deuterated compound of Cyclophosphamide. Cyclophosphamide has a CAS number of 50-18-0. Cyclophosphamide is an alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.

5-Hydroxy-8-methoxypsoralen (5-Hydroxyxanthotoxin) is a metabolite derived from Xanthotoxin, which acts as a potent tricyclic furocoumarin suicide inhibitor of CYP (cytochrome P-450). It is employed as an agent for the treatment of psoriasis, eczema, vitiligo, and certain cutaneous Lymphomas, in combination with phototherapy involving exposure to sunlight.

AZD5153 is a reversible inhibitor of BRD4, a bromodomain and extra-terminal family protein, with antitumor activity.AZD5153 inhibits hepatocarcinogenesis by altering the BRD4 chromosome landscape and regulating the transcriptome of HCC cells.AZD5153 is used in the study of lymphomas and solid tumors.

Cellocidin is a potent gammaherpesvirus-associated B-lymphomas growth inhibitor. It acts through the activation of both the NF-κB and c-Myc-mediated signaling pathways.

BC-23 (NSC 45382) is a potent proteasome inhibitor with antitumor and antimicrobial activity.BC-23 inhibits the CT-L activity of the proteasome and is used in the study of leukemias, lymphomas, gliomas, breast cancer, and small cell lung cancer.

Brentuximab vedotin (SGN-35) is an antibody-activated molecule coupling (ADC) targeting CD30 with antitumor activity for the study of lymphomas.

ATG-031 is a high affinity humanized anti-CD24 monoclonal antibody that shows antitumor activity in vitro and in vivo.ATG-031 blocks the CD24-Siglec10 axis in the TME.ATG-031 can be used to study non-Hodgkin's lymphomas and to modulate the tumor microenvironment.

Lenalidomide hydrochloride (CC-5013 hydrochloride), a Thalidomide derivative, functions as molecular glue and serves as an orally active immunomodulator. As a ligand for the ubiquitin E3 ligase cereblon (CRBN), it facilitates the selective ubiquitination and degradation of the lymphoid transcription factors IKZF1 and IKZF3 through the CRBN-CRL4 ubiquitin ligase. Specifically, Lenalidomide hydrochloride inhibits the growth of mature B-cell lymphomas, including multiple myeloma, and promotes IL-2 release from T cells [1] [2].

Forodesine (BCX-1777) is an orally active and potent purine nucleoside phosphorylase (PNP) inhibitor, a new purine nucleoside analog, inhibitor of human lymphocyte proliferation, induces apoptosis in leukemic cells by increasing dGTP levels, and may be useful in the study of cutaneous T-cell lymphomas.

MPT0E028 is an orally active and selective inhibitor of HDAC (IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2, and HDAC6, respectively). MPT0E028 has good anticancer activity. MPT0E028 decreases the viability of B-cell lymphomas by inducing apoptosis

Epratuzumab (Antibody hLL 2), an anti-CD22 IgG1 monoclonal antibody, serves as both a tumor-imaging and immunomodulatory agent. It induces CD22 phosphorylation and has been employed in researching Non-Hodgkin’s Lymphomas (NHL) and select autoimmune diseases [1].

Elimusertib (BAY-1895344) is a potent, highly selective and orally available ATR inhibitor with an IC50 of 7 nM.Elimusertib shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride.

Aclacinomycin A (Aclarubicin) is a novel anthracycline antibiotic isolated from Streptomyces galilei with antitumor activity.Aclacinomycin A is an inhibitor of topoisomerases I and II and inhibits RNA activity.Aclacinomycin A has been used in the study of relapsed leukemia and advanced malignant lymphomas.

CUDC-907 mesylate is a small molecule inhibitor of histone deacetylase and PI3 kinase developed by Curis. It is investigated in clinical trials for the treatment of relapsed or refractory lymphomas, thyroid cancer, multiple myeloma, breast cancer and other malignancies.

Cyclophosphamide-d8 is a deuterated compound of Cyclophosphamide. Cyclophosphamide has a CAS number of 50-18-0. Cyclophosphamide is an alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.

Vincristine binds to tubulin and inhibits the formation of microtubules, thereby inhibiting mitosis of the cancer cell. Vincristine can be used as a microtubule-destabilizing agent for research on the treatment of hematologic cancers, such as leukemia and

PSI (TFA) is a potent proteasome inhibitor effective against the proliferation of primary effusion lymphoma (PEL) cells, utilized in the study of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and related lymphomas [1].

Finotonlimab (SCT-I10A), a humanized IgG PD-1 monoclonal antibody, shows potential in the research of solid tumors or lymphomas [1].

Bendamustine (SDX105) for the treatment of Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

KC-11404 is an LTB4 inhibitor for the treatment of b-cell leukemias and lymphomas, potently inhibiting histamine, platelet activating factor and 5-lipoxygenase.

Tubulin polymerization-IN-36 is able to be used in cancer research, for example, lymphomas. Tubulin polymerization-IN-36 binds to the colchicine site of tubulin and inhibits colchicine binding, that is an inhibitor of tubulin polymerization with IC50 of 2.8 μΜ[1].

QL47 is a host-targeted small molecule antiviral agent with antiviral activity against dengue and other RNA viruses.QL47 acts as an inhibitor of viral translation and a covalent inhibitor of BTK, and can be used in the study of lymphomas.

EG-011, a first-in-class and potent activator of Wiskott-Aldrich syndrome protein (WASP), effectively activates the auto-inhibited form of WASP, leading to strong actin polymerization. This compound demonstrates selective anti-tumor activity in lymphomas.

Tubulin polymerization-IN-37 is a potent inhibitor (IC50: 2.3 μΜ) of tubulin polymerization by binding specifically to the colchicine site of tubulin and preventing colchicine binding. It has potential applications in cancer research, notably for lymphomas [1].

Cyclophosphamide is an alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.